Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01285102 · ClinicalTrials.gov registry record · Phase 1
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01285102 is a Phase 1 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 4 participants.
The verdict
NCT01285102, a Phase 1 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Chemoembolization kills tumor cells by blocking blood flow to the tumor and keeping chemotherapy drugs near the tumor. PURPOSE: This phase II trial is studying how well chemoembolization using irinotecan works in treating patients with liver metastases from metastatic colon or rectal cancer.
Interventions
- PROCEDURE hepatic artery embolization
- COMBINATION_PRODUCT irinotecan-eluting beads
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01285102
The ClinicalTrials.gov registry entry for NCT01285102 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which hepatic artery embolization is the first listed.
NCT01285102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01285102 about?
NCT01285102 is a clinical study titled "Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer". RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Chemoembolization kills tumor cells by blocking blood flow to the tumor and keeping chemotherapy drugs near t...
What is the current status of trial NCT01285102?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2010-10. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01285102?
The interventions under investigation include: hepatic artery embolization (PROCEDURE), irinotecan-eluting beads (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT01285102?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.